Discover
BMEA
Biomea Fusion, Inc.
1.33
45 x 1.31
1 x 1.45
bid
ask
+
0.00
0.00%
100 @ 04:00 PM
1.33 +0.00 (0.00%)
| Ytd | 7.26% | |
| 1y | -27.32% |
day range
0.87
52 week range
2.99
| Open | Prev Close | 1.33 | Low | High | Mkt Cap | 79.13M | |||
| Vol | 0.00 | Avg Vol | 1.14M | EPS | -1.59 | P/E | -0.84 | Forward P/E | -1.21 |
| Beta | -0.31 | Short Ratio | 12.98 | Inst. Own | 64.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 1.32 | 200-d Avg | 1.39 | 1yr Est | 40.56 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-10-29 | 2024-09 | -1.05 | -0.91 | 0.14 | 13.33% |
| 2024-07-31 | 2024-06 | -1.03 | -1.03 | N/A | N/A |
| 2024-07-31 | 2024-06 | -1.03 | N/A | N/A | N/A |
| 2024-05-02 | 2024-03 | -1.02 | -1.09 | -0.07 | -6.86% |
| 2024-05-02 | 2024-03 | -1.02 | N/A | N/A | N/A |
| 2024-04-01 | 2023-12 | -0.85 | -0.98 | -0.13 | -15.29% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-19 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-12-18 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-17 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-12-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-12-10 | D. Boral Capital | Upgrade | Buy | Buy |
| 2024-12-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-05-31 | A2A PHARMACEUTICALS INC | Beneficial Owner of more than 10% of a Class of Security | 3.50M | Sale |
| 2023-03-29 | CHEN BIHUA X. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2023-12-28 | ERDTMANN RAINER M | President | 2.53M | Stock Gift |
| 2024-05-30 | FRIAS JUAN PABLO | Officer | 349.00 | Stock Award(Grant) |
| 2024-09-29 | HITCHCOCK MICHAEL J.M. | Director | 15.00K | Purchase |
| 2024-11-28 | VALLE FRANCO | Chief Financial Officer | 43.00K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | FMR, LLC | 5.43M | 21.78M | 14.99% |
| 2024-09-29 | Cormorant Asset Management, LP | 3.57M | 14.32M | 9.85% |
| 2024-09-29 | Blackrock Inc. | 2.30M | 9.21M | 6.34% |
| 2024-09-29 | Baker Bros. Advisors, LP | 2.11M | 8.46M | 5.82% |
| 2024-09-29 | Vanguard Group Inc | 1.40M | 5.61M | 3.86% |
| 2024-09-29 | Millennium Management Llc | 1.38M | 5.53M | 3.80% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Growth Company Fund | 1.63M | 6.52M | 4.49% |
| 2024-10-30 | iShares Russell 2000 ETF | 718.87K | 2.88M | 1.98% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 711.77K | 2.85M | 1.96% |
| 2024-10-30 | Fidelity Growth Company K6 Fund | 620.20K | 2.49M | 1.71% |
| 2024-10-30 | Fidelity Series Growth Company Fund | 520.43K | 2.09M | 1.44% |
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 392.13K | 1.57M | 1.08% |